$CCEL
CRYO CELL INTERNATIONAL INC

2025 Q1 Form 10-K Financial Statement

#000095017025030138 Filed on February 28, 2025

View on sec.gov

Income Statement

Concept 2025 Q1 2024 Q4 2024
Revenue $31.99M
YoY Change 2.05%
Cost Of Revenue $7.948M
YoY Change -5.86%
Gross Profit $24.04M
YoY Change 4.96%
Gross Profit Margin 75.15%
Selling, General & Admin $18.52M
YoY Change 8.21%
% of Gross Profit 77.05%
Research & Development $1.243M
YoY Change 6.07%
% of Gross Profit 5.17%
Depreciation & Amortization $693.8K
YoY Change -50.43%
% of Gross Profit 2.89%
Operating Expenses $19.76M
YoY Change 8.08%
Operating Profit $3.480M
YoY Change -128.29%
Interest Expense $1.865M
YoY Change 50.77%
% of Operating Profit 53.58%
Other Income/Expense, Net -$676.2K
YoY Change -36.24%
Pretax Income $2.804M
YoY Change -120.98%
Income Tax $2.402M
% Of Pretax Income 85.66%
Net Earnings $402.1K
YoY Change -104.22%
Net Earnings / Revenue 1.26%
Basic Earnings Per Share $0.05
Diluted Earnings Per Share $0.05
COMMON SHARES
Basic Shares Outstanding 8.082M 8.062M 8.131M
Diluted Shares Outstanding 8.213M

Balance Sheet

Concept 2025 Q1 2024 Q4 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $561.0K
Short-Term Investments
Other Short-Term Assets $454.6K
YoY Change 16.58%
Inventory $657.7K
Prepaid Expenses $637.1K
Receivables $7.309M
Other Receivables
Total Short-Term Assets $12.55M
YoY Change 32.81%
LONG-TERM ASSETS
Property, Plant & Equipment $21.89M
YoY Change 4.27%
Goodwill $1.941M
YoY Change 0.0%
Intangibles $921.3K
YoY Change -6.86%
Long-Term Investments
YoY Change
Other Assets $30.23M
YoY Change -1.76%
Total Long-Term Assets $52.12M
YoY Change 0.69%
TOTAL ASSETS
Total Short-Term Assets $12.55M
Total Long-Term Assets $52.12M
Total Assets $64.68M
YoY Change 5.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.882M
YoY Change -40.71%
Accrued Expenses $5.810M
YoY Change 12.36%
Deferred Revenue $9.789M
YoY Change 0.87%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.60M
YoY Change 3.53%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $56.29M
YoY Change 9.55%
Total Long-Term Liabilities $56.29M
YoY Change 9.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.60M
Total Long-Term Liabilities $56.29M
Total Liabilities $77.89M
YoY Change 7.81%
SHAREHOLDERS EQUITY
Retained Earnings -$32.78M
YoY Change 5.19%
Common Stock $44.42M
YoY Change 1.97%
Preferred Stock
YoY Change
Treasury Stock (at cost) $24.86M
YoY Change 6.08%
Treasury Stock Shares
Shareholders Equity -$13.22M
YoY Change
Total Liabilities & Shareholders Equity $64.68M
YoY Change 5.65%

Cashflow Statement

Concept 2025 Q1 2024 Q4 2024
OPERATING ACTIVITIES
Net Income $402.1K
YoY Change -104.22%
Depreciation, Depletion And Amortization $693.8K
YoY Change -50.43%
Cash From Operating Activities $6.011M
YoY Change -32.61%
INVESTING ACTIVITIES
Capital Expenditures $2.404M
YoY Change -64.85%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.877M
YoY Change -40.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.424M
YoY Change 78.2%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -979.1K
YoY Change -52.77%
NET CHANGE
Cash From Operating Activities 6.011M
Cash From Investing Activities -4.877M
Cash From Financing Activities -979.1K
Net Change In Cash 154.9K
YoY Change -111.93%
FREE CASH FLOW
Cash From Operating Activities $6.011M
Capital Expenditures $2.404M
Free Cash Flow $3.607M
YoY Change 73.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-11-30
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
001-40767
CY2024 dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
CY2024 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1800
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
CY2024 dei City Area Code
CityAreaCode
813
CY2024 dei Local Phone Number
LocalPhoneNumber
749-2100
CY2024 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2024 dei Trading Symbol
TradingSymbol
CCEL
CY2024 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Public Float
EntityPublicFloat
43849869
CY2025Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8082159
CY2024 dei Auditor Firm
AuditorFirmId
344
CY2024 dei Auditor Name
AuditorName
Wipfli LLP
CY2024 dei Auditor Location
AuditorLocation
Atlanta, Georgia
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Amendment Flag
AmendmentFlag
false
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024 dei Document Type
DocumentType
10-K
CY2024 cyd Cybersecurity Risk Management Processes Integrated Flag
CybersecurityRiskManagementProcessesIntegratedFlag
true
CY2024 cyd Cybersecurity Risk Third Party Oversight And Identification Processes Flag
CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
true
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
560960
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
406067
CY2024Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2935183
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
574183
CY2024Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4266405
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3822300
CY2024Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7309094
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
637055
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
615407
CY2024Q4 us-gaap Inventory Net
InventoryNet
657703
CY2023Q4 us-gaap Inventory Net
InventoryNet
768877
CY2024Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
122113
CY2024Q4 us-gaap Other Assets Current
OtherAssetsCurrent
454598
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
389950
CY2024Q4 us-gaap Assets Current
AssetsCurrent
12554593
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9452837
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21894263
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20996883
CY2024Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
921254
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
989121
CY2024Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
4942115
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
5260119
CY2024Q4 us-gaap Goodwill
Goodwill
1941411
CY2023Q4 us-gaap Goodwill
Goodwill
1941411
CY2024Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20802023
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20492749
CY2024Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
806339
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1033157
CY2024Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
815635
CY2023Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
746493
CY2024Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30228777
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30771050
CY2024Q4 us-gaap Assets
Assets
64677633
CY2023Q4 us-gaap Assets
Assets
61220770
CY2024Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1882274
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3174584
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5809872
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5170809
CY2024Q4 us-gaap Notes Payable Current
NotesPayableCurrent
170488
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
165641
CY2024Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
3520000
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1222728
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
428334
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
225686
CY2024Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
0
CY2023Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1200000
CY2024Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9788574
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9704553
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21599542
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20864001
CY2024Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
46556990
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41186800
CY2024Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
47020
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
44226
CY2024Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8310045
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8430037
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
505053
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
851938
CY2024Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2024Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
56294108
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51388001
CY2024Q4 us-gaap Liabilities
Liabilities
77893650
CY2023Q4 us-gaap Liabilities
Liabilities
72252002
CY2024Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2024Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14869619
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8082159
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14849246
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8286785
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
148696
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
148492
CY2024Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
44268469
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43411143
CY2024Q4 us-gaap Treasury Stock Value
TreasuryStockValue
24855556
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
23431685
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32777626
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31159182
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-13216017
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11031232
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64677633
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61220770
CY2024 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31986106
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31343695
CY2024 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7947752
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8390463
CY2024 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18521218
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17167361
CY2024 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0
CY2023 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
3737133
CY2024 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
0
CY2023 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
13108064
CY2024 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2794
CY2022 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1050978
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1242536
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1171456
CY2024 us-gaap Depreciation And Amortization
DepreciationAndAmortization
483522
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1124228
CY2024 us-gaap Costs And Expenses
CostsAndExpenses
28505822
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
43647727
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
3480284
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-12304032
CY2024 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1076051
CY2023 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
50777
CY2024 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
105887
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
122113
CY2024 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6583
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3441
CY2024 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1864684
CY2023 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1236794
CY2024 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-676163
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1060463
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2804121
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13364495
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2402026
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3842826
CY2024 us-gaap Net Income Loss
NetIncomeLoss
402095
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-9521669
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8130676
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8340839
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8212510
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8340839
CY2024 us-gaap Profit Loss
ProfitLoss
402095
CY2023 us-gaap Profit Loss
ProfitLoss
-9521669
CY2024 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
693847
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1399667
CY2023 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
3737133
CY2024 ccel Impairment On Investment
ImpairmentOnInvestment
308000
CY2023 ccel Impairment On Investment
ImpairmentOnInvestment
0
CY2024 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
0
CY2023 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
13108064
CY2024 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2794
CY2023 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1050978
CY2024 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1076051
CY2023 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
50777
CY2024 ccel Realized And Unrealized Gain On Interest Rate Swap Contract
RealizedAndUnrealizedGainOnInterestRateSwapContract
105887
CY2023 ccel Realized And Unrealized Gain On Interest Rate Swap Contract
RealizedAndUnrealizedGainOnInterestRateSwapContract
122113
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
781128
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
816639
CY2024 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1266905
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1036390
CY2024 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-309274
CY2023 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-6750350
CY2024 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
21237
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
21631
CY2024 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
327750
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
310744
CY2024 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1999759
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1568689
CY2024 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
21648
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
48850
CY2024 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-429178
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-360445
CY2024 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
64648
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-36929
CY2024 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
69142
CY2023 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
99267
CY2024 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-423720
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
688935
CY2024 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
639063
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1582135
CY2024 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-245169
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-271232
CY2024 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
5454211
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
5304967
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6010910
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8919754
CY2024 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2403708
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6838969
CY2024 ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
1200000
CY2023 ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
799999
CY2024 ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
101873
CY2023 ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
179306
CY2024 ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
2891423
CY2023 ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1082923
CY2024 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1516359
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
397831
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4876899
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8144754
CY2024 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1423871
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
799036
CY2024 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
136382
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
156355
CY2024 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2922728
CY2023 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2000000
CY2024 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76402
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2024 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
5220000
CY2023 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
950000
CY2024 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
2020539
CY2023 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
CY2024 ccel Proceeds From Swap Termination
ProceedsFromSwapTermination
228000
CY2023 ccel Proceeds From Swap Termination
ProceedsFromSwapTermination
0
CY2024 ccel Payment Of Earnout
PaymentOfEarnout
0
CY2023 ccel Payment Of Earnout
PaymentOfEarnout
67500
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-979118
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2072891
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
154893
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1297891
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
406067
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1703958
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
560960
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
406067
CY2024 ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
100932
CY2023 ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
737867
CY2024 ccel Construction Costs Payable
ConstructionCostsPayable
-880348
CY2023 ccel Construction Costs Payable
ConstructionCostsPayable
880348
CY2024 us-gaap Interest Paid Net
InterestPaidNet
1976808
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1808751
CY2024 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2716993
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1820802
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-2864
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
816639
CY2023 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
799036
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-9521669
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11031232
CY2024 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76402
CY2024 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
781128
CY2024 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1423871
CY2024 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.25
CY2024 us-gaap Dividends Common Stock
DividendsCommonStock
2020539
CY2024 us-gaap Net Income Loss
NetIncomeLoss
402095
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
-13216017
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Risks</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company depends on one supplier for the source of its collection kits</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units. However, the Company believes that alternative sources of supply and manufacturing are available.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During fiscal 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were no concentration of risks.</span></p>
CY2024 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
The Company depends on one supplier for the source of its collection kits
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statements </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p>
CY2024Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
56345564
CY2024Q4 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9788574
CY2024Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2024 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
45375
CY2022 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
41056
CY2024 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
118498
CY2023 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
114139
CY2024Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
775147
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
695695
CY2024Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7309094
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9788574
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9704553
CY2024Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
46556990
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41186800
CY2024 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2023 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
695695
CY2024 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
118498
CY2024 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
39046
CY2024Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
775147
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
42735527
CY2024 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
42002673
CY2024Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7309094
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
50891353
CY2024 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
21665729
CY2024 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
16211518
CY2024Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
56345564
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
CY2023 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
114139
CY2023 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
34072
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
695695
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
CY2023 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
34592477
CY2023 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
34060178
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
45586386
CY2023 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
24738156
CY2023 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
19433189
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
50891353
CY2024 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2024 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2023 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2024 us-gaap Advertising Expense
AdvertisingExpense
1067392
CY2023 us-gaap Advertising Expense
AdvertisingExpense
952586
CY2024 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
105887
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
122113
CY2024 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Warranty and Cryo-Cell Cares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Program</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payment warranty to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warranty </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program, nor has it incurred costs related to these warranties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at November 30, 2024 and November 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2024 us-gaap Net Income Loss
NetIncomeLoss
402095
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-9521669
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8130676
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8340839
CY2024 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
81834
CY2023 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8212510
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8340839
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
CY2024 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
781000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
817000
CY2024 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no material effect on the reported results of operations.</span></p>
CY2024Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0
CY2023Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
3737133
CY2024Q4 ccel Inventory Collection Kits
InventoryCollectionKits
48813
CY2023Q4 ccel Inventory Collection Kits
InventoryCollectionKits
47739
CY2024Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2024Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
5599818
CY2023Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
6028996
CY2024Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
921254
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
989121
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
58180
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
44618
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
44618
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
44618
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
44435
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
684785
CY2024Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
921254
CY2024 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
96000
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
228000
CY2024Q4 us-gaap Ratio Of Indebtedness To Net Capital1
RatioOfIndebtednessToNetCapital1
3.5
CY2024 ccel Minimum Debt Service Coverage Ratio
MinimumDebtServiceCoverageRatio
1.25
CY2024Q4 us-gaap Long Term Debt
LongTermDebt
8480533
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8595678
CY2024Q4 us-gaap Notes Payable Current
NotesPayableCurrent
170488
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
165641
CY2024Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8310045
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8430037
CY2024Q4 us-gaap Long Term Debt
LongTermDebt
8480533
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8595678
CY2024Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
170488
CY2024Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
187035
CY2024Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
201985
CY2024Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
213753
CY2024Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
227438
CY2024Q4 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
7628001
CY2024Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
148167
CY2024Q4 us-gaap Long Term Debt
LongTermDebt
8480533
CY2024 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
532188
CY2023 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
140589
CY2024 us-gaap Interest Costs Incurred
InterestCostsIncurred
941495
CY2023 us-gaap Interest Costs Incurred
InterestCostsIncurred
824113
CY2024 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
409307
CY2023 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
683524
CY2024 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
532188
CY2023 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
140589
CY2024 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31986106
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31343695
CY2024 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7947752
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8390463
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
3480284
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-12304032
CY2024 us-gaap Interest Expense
InterestExpense
1864684
CY2023 us-gaap Interest Expense
InterestExpense
1236794
CY2024Q4 us-gaap Assets
Assets
64677633
CY2023Q4 us-gaap Assets
Assets
61220770
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3528119
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1036390
CY2023 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
954467
CY2023 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
212258
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3822300
CY2024 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1266905
CY2024 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1170499
CY2024 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
347699
CY2024Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4266405
CY2024Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27536912
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29129991
CY2024Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5642649
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8133108
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21894263
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20996883
CY2024 us-gaap Depreciation
Depreciation
626000
CY2023 us-gaap Depreciation
Depreciation
326000
CY2024 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
119000
CY2023 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
172000
CY2024 ccel Research Development And Related Engineering
ResearchDevelopmentAndRelatedEngineering
93000
CY2023 ccel Research Development And Related Engineering
ResearchDevelopmentAndRelatedEngineering
87000
CY2024 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
409307
CY2023 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
683524
CY2024Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
73331
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
78964
CY2024Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
2121061
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
2061595
CY2024Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1382068
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1111853
CY2024Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
812628
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
491920
CY2024Q4 ccel Accrued Income Taxes Benefit Current
AccruedIncomeTaxesBenefitCurrent
1420784
CY2023Q4 ccel Accrued Income Taxes Benefit Current
AccruedIncomeTaxesBenefitCurrent
1426477
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5809872
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5170809
CY2024 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
2085000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1862000
CY2024 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
626000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1046000
CY2024 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2024 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2711000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2908000
CY2024 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1190000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-4945000
CY2024 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
881000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1806000
CY2024 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2024 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-309000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6751000
CY2024 ccel Income Tax Expense Benefit Including Current And Deferred
IncomeTaxExpenseBenefitIncludingCurrentAndDeferred
2402000
CY2023 ccel Income Tax Expense Benefit Including Current And Deferred
IncomeTaxExpenseBenefitIncludingCurrentAndDeferred
-3843000
CY2024Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
12954000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11945000
CY2024Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1272000
CY2023Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1268000
CY2024Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
444000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
465000
CY2024Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
3661000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
3585000
CY2024Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
452000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
578000
CY2024Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
3348000
CY2023Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
3938000
CY2024Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
19000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
20000
CY2024Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
883000
CY2023Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1097000
CY2024Q4 ccel Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
248000
CY2023Q4 ccel Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
305000
CY2024Q4 ccel Deferred Tax Assets Tax Deferred Expense Unrealized Gain Loss On Securities
DeferredTaxAssetsTaxDeferredExpenseUnrealizedGainLossOnSecurities
-55000
CY2023Q4 ccel Deferred Tax Assets Tax Deferred Expense Unrealized Gain Loss On Securities
DeferredTaxAssetsTaxDeferredExpenseUnrealizedGainLossOnSecurities
105000
CY2024Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
505000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
268000
CY2024Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23731000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23574000
CY2024Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1211000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1273000
CY2024Q4 ccel Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
214000
CY2023Q4 ccel Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
292000
CY2024Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1425000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1565000
CY2024Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1504000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1516000
CY2024Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
20802000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
20493000
CY2024 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-12000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-6000
CY2024 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
588866
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2806544
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
239410
CY2024 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0853
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-924411
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0692
CY2024 ccel Income Tax Reconciliation Increase Decrease In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationIncreaseDecreaseInDeferredTaxAssetsValuationAllowance
-12097
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0043
CY2023 ccel Income Tax Reconciliation Increase Decrease In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationIncreaseDecreaseInDeferredTaxAssetsValuationAllowance
5869
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0004
CY2024 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
139893
CY2024 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0499
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
94115
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.007
CY2024 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
48811
CY2024 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.0174
CY2023 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
50322
CY2023 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
-0.0038
CY2024 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
1314454
CY2024 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
0.4688
CY2023 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
-98419
CY2023 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
0.0074
CY2024 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0
CY2024 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
41220
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0032
CY2024 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
-4213
CY2024 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
-0.0015
CY2023 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
-204978
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
0.0153
CY2024 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
86902
CY2024 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.031
CY2023 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2402026
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.8566
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3842826
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2875
CY2024 ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
70000
CY2024 us-gaap Unrecognized Tax Benefits Increases Resulting From Acquisition
UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
0
CY2024 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
70000
CY2024 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2024 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2024Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
2717000
CY2023 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
1821000
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.22
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.29
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
493878
CY2024 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y9M29D
CY2024Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.26
CY2024Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
361918
CY2024Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
7.68
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
114193
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.1
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
113600
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.22
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
95833
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.35
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2024Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
131960
CY2024Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.03
CY2004Q2 ccel Operating Lease Period
OperatingLeasePeriod
P10Y
CY2004Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17.600
CY2018Q3 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600
CY2021Q1 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600
CY2024Q2 ccel Extension Lease Period
ExtensionLeasePeriod
P2Y
CY2024 us-gaap Operating Lease Expense
OperatingLeaseExpense
442874
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
400716
CY2024 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15
CY2024 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
227000
CY2023 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
212000
CY2024 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
1058311
CY2023 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
1009813
CY2011Q4 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
CY2024 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2024Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6787460
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6562461
CY2024Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
806339
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1033157
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
428334
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
225686
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
505053
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
851938
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
933387
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1077624
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
490310
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
490982
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
38247
CY2024Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
86152
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
933387
CY2024Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y29D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y29D
CY2024Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2024 us-gaap Operating Lease Payments
OperatingLeasePayments
355140
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
330455
CY2023Q4 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
13108064
CY2024Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-25-030138-index-headers.html Edgar Link pending
0000950170-25-030138-index.html Edgar Link pending
0000950170-25-030138.txt Edgar Link pending
0000950170-25-030138-xbrl.zip Edgar Link pending
ccel-20241130.htm Edgar Link pending
ccel-20241130.xsd Edgar Link pending
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img17314691_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
ccel-20241130_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable